Calcitonin Gene-Related Peptide Receptor Antagonist Market Report 2025

The calcitonin gene-related peptide receptor antagonist market size has grown rapidly in recent years. It will grow from $2.06 billion in 2024 to $2.3 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. Growth during the historic period can be attributed to the expansion of clinical trials validating the efficacy of CGRP antagonists, increased global healthcare spending, higher diagnosis rates of migraine disorders, greater adoption of preventive migraine therapies, and a robust development pipeline of CGRP antagonist compounds.

The calcitonin gene-related peptide receptor antagonist market size is expected to see rapid growth in the next few years. It will grow to $3.48 billion in 2029 at a compound annual growth rate (CAGR) of 11%. Growth in the forecast period can be attributed to favorable regulatory approvals, increased research funding, rising adoption of innovative migraine prevention therapies, and a growing geriatric population. Key trends expected during this period include the development of oral small molecule therapies, wearable-triggered dosing devices, long-acting injectable formulations, nanoparticle-based drug delivery systems, and ongoing investigations into gene therapy approaches.

The rising prevalence of migraines is expected to drive the growth of the calcitonin gene-related peptide receptor antagonist market in the coming years. Migraines are severe headaches characterized by throbbing pain, often localized to one side of the head. The increase in migraine cases is attributed to heightened stress from hectic urban lifestyles, irregular sleep patterns, and greater exposure to noise, pollution, and bright lights as more people relocate to cities. Calcitonin gene-related peptide receptor antagonists work by blocking CGRP, a protein that causes blood vessels to widen and transmits pain signals during migraine attacks, thereby alleviating headache pain and related symptoms. For example, a report published by the National Library of Medicine in April 2024 noted that about 61,204 individuals in the US were diagnosed with migraines by a physician in 2022, marking a 5.5% increase from 2021. This growing incidence of migraines is fueling the market expansion for CGRP receptor antagonists.

Leading companies in the calcitonin gene-related peptide receptor antagonist market are emphasizing the approval of innovative therapies, including oral CGRP receptor antagonists, which aim to improve the effectiveness of migraine treatments, broaden therapeutic uses, and offer more convenient dosing options. Oral CGRP receptor antagonists are small-molecule drugs that block CGRP, a protein associated with migraine episodes, and help in migraine prevention. For instance, in April 2023, AbbVie Inc., a US biotechnology firm, received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) to treat chronic migraine in adults. QULIPTA is an oral, once-daily CGRP receptor antagonist designed for the preventive treatment of migraines in adults, approved for both episodic and chronic migraines in the United States. It functions by inhibiting CGRP, a protein elevated during migraine attacks that contributes to pain signaling and brain inflammation. QULIPTA is available in tablet strengths of 10 mg, 30 mg, and 60 mg, with the 60 mg dosage specifically evaluated for chronic migraine prevention.

In October 2022, Pfizer Inc., a US pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for an undisclosed amount. Through this acquisition, Pfizer intends to enhance its migraine treatment portfolio and support long-term growth by combining Biohaven’s innovative therapies with Pfizer’s global distribution capabilities to better serve patients worldwide. Biohaven Pharmaceutical Holding Company Ltd. is a US biopharmaceutical company specializing in calcitonin gene-related peptide receptor antagonists for migraine therapy.

Major players in the calcitonin gene-related peptide receptor antagonist market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Sosei Group Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., Alder BioPharmaceuticals, Inc., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd., Biosynth Carbosynth, Seurat Therapeutics Inc., Satsuma Pharmaceuticals Inc., Allergan plc, Brise Pharmaceutical (Shanghai) Co Ltd., Nuvie Biopharma Inc.

North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin gene-related peptide receptor antagonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the calcitonin gene-related peptide receptor antagonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcitonin gene-related peptide receptor antagonist market consists of sales of atogepant, orally disintegrating CGRP receptor, and intranasal CGRP receptor antagonist sprays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The calcitonin gene-related peptide receptor antagonist market research report is one of a series of new reports that provides calcitonin gene-related peptide receptor antagonist market statistics, including calcitonin gene-related peptide receptor antagonist industry global market size, regional shares, competitors with a calcitonin gene-related peptide receptor antagonist market share, calcitonin gene-related peptide receptor antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide receptor antagonist industry. This calcitonin gene-related peptide receptor antagonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of medications designed to block the effects of CGRP, a molecule that plays a key role in transmitting pain signals and dilating blood vessels in order to prevent or treat migraines and cluster headaches. These drugs offer targeted relief from migraines and generally result in fewer side effects than traditional migraine treatments, thereby enhancing patient outcomes and overall quality of life.

The primary categories of CGRP receptor antagonists include small molecule antagonists, monoclonal antibodies, and peptide-based antagonists. Small molecule antagonists are low-molecular-weight compounds that inhibit specific proteins like the CGRP receptor, aiding in the prevention or reduction of migraine symptoms. Common drugs in this class include zavegepant, ubrogepant, olcegepant, telcegepant, rimegepant, and others. These medications are used across various applications, such as migraine treatment, pain management, cardiovascular conditions, and bone disorders, and are utilized by end users including hospitals, clinics, homecare settings, and pharmaceutical companies.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.